Fungicidal VS. Fungistatic

Fungistatic drugs can only inhibit growth, keeping the fungal pathogens at bay without ever fully eliminating them.4 Fungicidal drugs, however, actively work to kill fungal pathogens.5

Product Drug
Classification
Mechanism
of Action
Organisms
Treated
Formulation Dosage
NAFTIN®
GEL 2%
(naftifine
hydrochloride)1
Allylamine Fungicidal T. rubrum
T. mentagrophytes
E. floccosum
Rapid-drying
hydrogel6
Once daily for
2 weeks
Luzu®
(luliconazole)7
Azole Fungistatic8 T.rubrum
E.floccosum
Cream Once daily for
2 weeks
Ecoza®
(econazole
nitrate)9
Azole Fungistatic8 T.rubrum
T.mentagrophytes
E.floccosum
Foam Once daily for
4 weeks

There have been no comparative clinical trials conducted between these products or active ingredients.

Because azoles have seen widespread clinical use, fungal pathogens have built a resistance to them over time.10 But NAFTIN GEL 2% is an allylamine, which means it is chemically distinct from azole-based antifungal agents.1 Fungal resistance to allylamines has not been observed in clinical use.1,10

The #1 Prescribed Brand for Interdigital Tinea Pedis2

Low-alcohol formulation for 0.4% incidence of burning2*

Reservoir with active ingredient remains 4 weeks after treatment3

Statistically significant cure rates with once-daily, 2-week dosing12

Proven effective and safe fungicidal allylamine1

*NAFTIN GEL 2% has a lower incidence of burning sensation compared with NAFTIN GEL 1%11

ExpandCollapseClick to expand complete Important Safety Information.Close

INDICATIONS AND USAGE: NAFTIN GEL 2% is an allylamine antifungal indicated for the treatment of interdigital tinea pedis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum in patients 12 years of age and older.

IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS: In clinical trials with NAFTIN GEL 2%, the most common adverse reactions (2%) were application site reactions.

WARNINGS AND PRECAUTIONS: If redness or irritation develops with the use of NAFTIN GEL 2%, treatment should be discontinued.

Please click here for full Prescribing Information about NAFTIN GEL 2%.

REFERENCES: 1. Vlahovic TC. Choosing the right vehicle. Podiatr Manage. June/July 2008;209-218. 2. Data on file, Sebela Pharmaceuticals. 3. NAFTIN (naftifine hydrochloride) Gel 2% [package insert]. Roswell, GA; Sebela Pharmaceuticals; 2020. 4. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US Food and Drug Administration/Center for Drug Evaluation and Research website. https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=001&Appl_No=204286&Appl_type=N. Accessed February 20, 2020. 5. Plaum S, Verma A, Fleischer AB, Olayinka B, Hardas B. Detection and relevance of naftifine hydrochloride in the stratum corneum up to four weeks following the last application of naftifine cream or gel 2%. J Drugs Dermatol. 2013;12(9):1004-1008. 6. Stein Gold L, Parish L, Vlahovic T, Kircik L, et al. Efficacy and safety of naftifine HCL Gel 2% in the treatment of interdigital and moccasin type tinea pedis: pooled results from two multicenter, randomized, double-blind, vehicle-controlled trials. J Drugs Dermatol. 2013;12(8):911-918. 7. Brennan B, Leyden JJ. Overview of topical therapy for common superficial fungal infections and the role of new topical agents. J Am Acad Dermatol. 1997;36:S3-S8. 8. NAFTIN 2% Co-Pay Savings Offer. Sebela Pharmaceuticals, December 2019. 9.  Parish LC, Parish JL, Routh HB, et al. A randomized, double-blind, vehicle-controlled efficacy and safety study of naftifine 2% cream in the treatment of tinea pedis. J Drugs Dermatol. November 2011;10(11):1282-1288. 10. Parish LC, Parish JL, Routh HB, et al. A double-blind, randomized, vehicle-controlled study evaluating the efficacy and safety of naftifine 2% cream in tinea cruris. J Drugs Dermatol. October 2011;10(10):1142-1147. 11. Robbins CM, Elston DM. Tinea pedis treatment & management. Medscape Web site. http://emedicine.medscape.com/article/1091684-overview. Updated November 19, 2015. Accessed February 22, 2016. 12. Phillips, RM, Rosen T. Topical antifungal agents. Allylamines and benzylamines. In: Wolverton, SE, ed. Comprehensive Dermatologic Drug Therapy. 3rd ed. Elsevier Inc. Ebook; 2013:460-472. 13. IQVIA. National Prescription Audit Report. March 2021.